Sapan Ghai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAshmore Regulatory News (ASHM)

Share Price Information for Ashmore (ASHM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 198.70
Bid: 198.60
Ask: 198.90
Change: 2.40 (1.22%)
Spread: 0.30 (0.151%)
Open: 196.30
High: 199.00
Low: 196.30
Prev. Close: 196.30
ASHM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Announcement of Placing Price

12 Oct 2006 07:00

Ashmore Group PLC 12 October 2006 These written materials are not for distribution (directly or indirectly) in or to the United States, Canada, Australia or Japan. They are not an offer of securities for sale in or into the United States, Canada, Australia or Japan. The Shares of the Company are not being registered under the US Securities Act of 1933, as amended (the 'Securities Act') and may not be offered or sold in the United States unless registered under the Securities Act or pursuant to an exemption from such registration. No money, securities or other consideration is being solicited and, if sent in response to the information contained herein, will not be accepted. 12th October 2006 Ashmore Group plc ('Ashmore' or the 'Company') Announcement of Placing Price of 170 pence per ordinary share Ashmore, the specialist emerging markets asset management company, today announces the successful pricing of its initial public offering of ordinary shares (the 'IPO'). • The placing price has been set at 170 pence per ordinary share (the 'Placing Price'). • Based upon the Placing Price, the market capitalisation of Ashmore at the commencement of conditional dealings will be approximately £1,205m. • The IPO consists of 177.3m Ashmore ordinary shares (prior to the utilisation of the over-allotment option), in total representing 25% of the 708.9m Ashmore ordinary shares in issue and implies an offer value of approximately £301m. • As stabilising manager, UBS Limited ('UBS') has been granted an over-allotment option of up to 17.7m ordinary shares, representing 10% of the ordinary shares in the IPO exercisable for a period of 30 days from today. • Conditional dealings are expected to commence on the London Stock Exchange at 8:00am today (12 October) under the ticker symbol ASHM. Admission to the Official List of the Financial Services Authority and commencement of unconditional dealings on the main market for listed securities of the London Stock Exchange plc (together, 'Admission') is expected to take place at 8:00am on 17 October 2006. • Directors, employees and their related interests will continue to hold approximately 75% of the Company's ordinary shares following the Placing (prior to the utilisation of the over-allotment option). The Company, employees and existing shareholders are subject to lock-ups of various periods following Admission. Goldman Sachs International ('Goldman Sachs') and UBS are acting as joint global co-ordinators, joint bookrunners and joint sponsors to Ashmore in relation to the IPO. Mark Coombs, Chief Executive, commented: 'The IPO demonstrates investors' confidence in our business and represents the logical next step in the development of Ashmore. The business is well-positioned to deliver further growth. We are all looking forward to finding more investment themes and diversified sources of returns for investors in our funds, and working for all shareholders to take the business to the next stage.' For further information, please contact: Penrose Financial Gay Collins +44 (0)20 7786 4882/07798 626282 Ben Curson +44 (0)20 7786 4870 Ashmore Group plc Jim Pettigrew +44 (0)20 7557 4175 Goldman Sachs International +44 (0)20 7774 1000 Joshua Critchley (ECM) Andrea Ponti Jonathan Sorrell UBS Investment Bank +44 (0)20 7567 8000 Adrian Lewis (ECM) John Humphrey Tom Shippey IMPORTANT INFORMATION This announcement has been issued by Ashmore Group plc ('Ashmore') of 20 Bedfordbury, London WC2N 4BL and is the sole responsibility of Ashmore and has been approved solely for the purposes of Section 21 of the Financial Services and Markets Act 2000 by UBS Limited ('UBS' or 'UBS Investment Bank') of 1 Finsbury Avenue, London EC2M 2PP and Goldman Sachs International ('Goldman Sachs') of Peterborough Court, 133 Fleet Street, London EC4A 2BB. Goldman Sachs and UBS are each acting exclusively for Ashmore and no-one else in connection with the IPO and will not be responsible to anyone other than Ashmore for providing the protections afforded to respective clients of Goldman Sachs and UBS or for providing advice in connection with the IPO. This announcement constitutes an advertisement within the meaning of the Prospectus Rules of the Financial Services Authority (the 'FSA') and is not a prospectus. The announcement does not constitute or form part of any offer of securities, or constitute a solicitation of any offer to purchase or subscribe for securities. Investors should not subscribe for shares in Ashmore except on the basis of information to be contained in a prospectus which it is intended will be approved by the FSA in accordance with the Prospectus Rules made under section 73A of the Financial Services and Markets Act 2000, in connection with the IPO, and any supplement to that Prospectus. The prospectus will contain certain detailed information about Ashmore and its management, as well as financial statements and other financial data. Copies of the prospectus will be available after its approval by the FSA and publication, from the offices of Ashmore at 20 Bedfordbury, London WC2N 4BL. No representation or warranty, express or implied, is made or given by or on behalf of Ashmore, Goldman Sachs or UBS or any of their respective affiliates or any of such person's directors, officers or employees or any other person as to the accuracy, completeness or fairness of the information or opinions contained in this announcement and no responsibility or liability is accepted for any such information or opinions. Certain statements in this announcement may be 'forward-looking statements'. The forward-looking statements can be identified by use of forward-looking terminology, including the terms 'believes', 'estimates', anticipates', 'projects', 'expects', 'intends', 'may', 'will', 'seeks' or 'should'or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, aims, objectives, goals, future events or intentions. Subject to any obligations under the listing rules of the UK Listing Authority following the IPO, Ashmore undertakes no obligation to update publicly or revise forward-looking statements, except as required by law. Such statements are based on current expectations and are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. This announcement does not constitute a recommendation concerning the IPO. The value of shares can go down as well as up. Past performance is not a guide to future performance. Potential investors should consult a professional adviser as to the suitability of any offering for the individual concerned. FSA/Stabilisation
Date   Source Headline
1st May 20243:01 pmRNSDirectorate Change
1st May 202411:11 amRNSDirector/PDMR Shareholding
18th Apr 20241:11 pmRNSDirectorate Change
15th Apr 20247:00 amRNSTrading Statement
18th Mar 20243:30 pmRNSDirector/PDMR Shareholding
7th Feb 20247:00 amRNSHalf-year Report
15th Jan 20247:00 amRNSTrading Statement
21st Dec 20239:30 amRNSHolding(s) in Company
11th Dec 202311:21 amRNSDirector/PDMR Shareholding
18th Oct 20232:13 pmRNSResult of AGM
13th Oct 20237:00 amRNSTrading Statement
19th Sep 202311:00 amRNSDirector/PDMR Shareholding
19th Sep 202310:08 amRNSHolding(s) in Company
15th Sep 20235:06 pmRNSHolding(s) in Company
14th Sep 20232:56 pmRNSNotice of AGM
14th Sep 202310:29 amRNSDirector/PDMR Shareholding
6th Sep 20237:00 amRNSFinal Results
14th Jul 20231:51 pmRNSHolding(s) in Company
14th Jul 20237:00 amRNSTrading Statement
11th Jul 20232:10 pmRNSHolding(s) in Company
10th Jul 20232:48 pmRNSHolding(s) in Company
30th Jun 20235:11 pmRNSHolding(s) in Company
29th Jun 20239:09 amRNSHolding(s) in Company
14th Jun 20239:23 amRNSHolding(s) in Company
19th May 20238:35 amRNSDirector Declaration
21st Apr 20237:00 amRNSDirectorate Change
17th Apr 20237:00 amRNSTrading Statement
14th Apr 20239:30 amRNSAGM Statement
31st Mar 20232:33 pmRNSDirector/PDMR Shareholding
17th Mar 202310:21 amRNSDirector/PDMR Shareholding
13th Mar 202310:23 amRNSAudit tender process
8th Mar 20239:48 amRNSHolding(s) in Company
27th Feb 20239:41 amRNSHolding(s) in Company
16th Feb 20234:53 pmRNSHolding(s) in Company
8th Feb 20237:00 amRNSHalf-year Report
3rd Feb 20233:02 pmRNSHolding(s) in Company
25th Jan 20233:25 pmRNSHolding(s) in Company
24th Jan 20236:12 pmRNSHolding(s) in Company
23rd Jan 20239:01 amRNSHolding(s) in Company
19th Jan 20234:55 pmRNSHolding(s) in Company
16th Jan 20237:00 amRNSTrading Statement
12th Jan 20233:26 pmRNSHolding(s) in Company
11th Jan 20234:27 pmRNSHolding(s) in Company
9th Jan 20233:13 pmRNSHolding(s) in Company
5th Jan 20235:14 pmRNSHolding(s) in Company
16th Dec 20223:52 pmRNSHolding(s) in Company
8th Nov 20224:20 pmRNSHolding(s) in Company
28th Oct 202210:13 amRNSHolding(s) in Company
14th Oct 20222:11 pmRNSResult of AGM
14th Oct 20227:00 amRNSTrading Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.